Clinical Trials Logo

Filter by:
NCT ID: NCT00162175 Completed - Clinical trials for Metabolics Diabetes Nos

PPAR-COMBO With Sulfonylurea

Start date: July 2003
Phase: Phase 3
Study type: Interventional

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone.

NCT ID: NCT00162123 Completed - Melanoma Clinical Trials

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment. In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.

NCT ID: NCT00160706 Completed - Crohn's Disease Clinical Trials

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

PRECiSE 4
Start date: February 2004
Phase: Phase 3
Study type: Interventional

A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] due to an exacerbation of Crohn's Disease.

NCT ID: NCT00160641 Completed - Clinical trials for Rheumatoid Arthritis

A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Start date: November 2005
Phase: Phase 3
Study type: Interventional

An open ended study in which patients who completed the preceding double-blind study NCT00160602 are given Certolizumab Pegol and assessed for signs and symptoms of Rheumatoid Arthritis.

NCT ID: NCT00160602 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Start date: June 2005
Phase: Phase 3
Study type: Interventional

A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.

NCT ID: NCT00160524 Completed - Crohn's Disease Clinical Trials

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

PRECiSE 3
Start date: July 2004
Phase: Phase 3
Study type: Interventional

An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]).

NCT ID: NCT00160342 Completed - Clinical trials for Hot Flushes, Menopause, Postmenopause

Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes

Start date: June 2005
Phase: Phase 2
Study type: Interventional

This is a research study to evaluate the effectiveness, safety and side effects of several dose levels of esterified estrogens (EE) and methyltestosterone (MT) given individually and in combination compared to a placebo (a tablet with no active drug in it) as a possible treatment for vasomotor symptoms (such as hot flushes and flushing) of menopause. EE and testosterone are two hormones which are typically deficient in menopausal women

NCT ID: NCT00159913 Completed - Clinical trials for Pulmonary Arterial Hypertension, Children

A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.

Start date: August 2003
Phase: Phase 3
Study type: Interventional

This is a clinical research study designed to evaluate sildenafil for the treatment of Pulmonary Arterial Hypertension in children, aged 1 to 17 years. The purpose of the study is to assess the efficacy, safety, and pharmacokinetics of 16 weeks of chronic treatment with oral sildenafil given in three different doses, compared to placebo (inactive treatment). Efficacy will be measured by exercise and hemodynamics. Patients who complete this trial may be eligible to take part in an extension study, in which all patients will receive active treatment of sildenafil.

NCT ID: NCT00159874 Completed - Clinical trials for Pulmonary Arterial Hypertension

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

Start date: January 2004
Phase: Phase 3
Study type: Interventional

Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.

NCT ID: NCT00158756 Completed - Hepatitis B Clinical Trials

Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants

Start date: September 12, 2005
Phase: Phase 3
Study type: Interventional

To compare the two formulations of GSK Biologicals' DTPw-HBV vaccine to concomitant administration of CSL's DTPw vaccine and GSK Biologicals' HBV with respect to the antibody response to the diphtheria antigen after a three-dose primary vaccination course.